Response's flu test:
This article was originally published in Clinica
Executive Summary
Response Biomedical has received US 510(k) clearance of its influenza A and B diagnostic, Flu A+B test. The rapid, point-of-care test will run on the Vancouver, Canada-based firm's new RAMP analyser platform, the RAMP 200. It will be marketed and sold exclusively worldwide by 3M Health Care as the 3M Rapid Detection Flu A+B Test. Response filed the 510(k) application in June 2007 (see Clinica No 1260, p 22). 3M Health Care plans to launch the test before the 2008-09 flu season in certain markets, and added it would be the first product sold in the US as part of its medical diagnostics platform.
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.